产品名称Sorafenib

简述Inhibitors

纯化99.80%

生物活性Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney Y). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver Y), and has since performed well in Phase ⅡI trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

基因/蛋白名称Raf inhibitor; VEGFR inhibitor

CAS号284461-73-0

计算分子量464.83

配方C21H16ClF3N4O3

保存3 years -20˚C powder;2 years -80˚C in solvent;